C-Path Partners with Matrix to Expand Rare Disease Data and Analytics Platform

We're delighted to see the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP), built and hosted on the Aridhia DRE, take another major step forward. This week Critical Path Institute (C-Path) announced a new partnership with Across Healthcare, whose Matrix platform will feed de-identified patient data directly into RDCA-DAP through a continuous digital pipeline, bringing real-world data (RWD) directly to researchers on the platform.

Aridhia C-Path Partnership

World Leading Rare Disease Research Platform

RDCA-DAP is one of the most ambitious integrated data platforms in the rare disease space, standardising natural history studies, patient registries and clinical trial data so that researchers can analyse it together.

In a field where rare diseases may only have a few hundred documented patients worldwide, that mission depends on infrastructure that can be trusted with sensitive patient data. It's a role the Aridhia DRE has supported for C-Path since the platform's inception: providing a secure, governed, cloud-based environment where regulators, researchers, and industry partners can work with rare disease data at scale without ever compromising patient privacy.

We're proud that RDCA-DAP continues to be the backbone C-Path and its many collaborators rely on to turn scattered, hard-to-find rare disease data into something researchers can actually use. It helps bring the platform's mission to life to accelerate research, improve clinical trial designs, and lead to more effective treatments for people living with a rare disease.

Rare Disease Research Poses Unique Challenges

In the rare disease space, research faces a problem common data-sharing models simply weren't built for. Any single rare disease may have only a few hundred documented patients worldwide, scattered across registries, clinics and countries. Bringing that data together, safely and at meaningful scale, is one of the hardest problems in health data research.

This is where the new RDCA-DAP integration offers a solution to that quandary. Rather than depending on manual data transfers and disconnected repositories, Matrix will now feed de-identified data straight into RDCA-DAP's data and analytics hub as it becomes available. That means researchers working on rare disease natural history and clinical trial design get access to more current data, and communities that have spent years building patient registries see that effort turned into research faster.

The first datasets moving through the new pipeline support three rare genetic conditions: GLUT1 Deficiency Syndrome, a metabolic disorder affecting glucose transport to the brain; RUNX1 Familial Platelet Disorder, an inherited blood disorder linked to elevated leukemia risk; and Shwachman-Diamond Syndrome, which affects bone marrow, pancreatic and skeletal development. Once integrated, this data can be cross-referenced against other sources already inside RDCA-DAP, helping researchers study disease progression and work toward measurable endpoints for future clinical trials.

Catalysts in Data Sharing

None of this would be possible without C-Path and the trusted relationships they've forged with patient advocacy organisations who made these datasets available in the first place: the GLUT1 Deficiency Foundation, the RUNX1 Research Program, and the Shwachman-Diamond Syndrome Alliance. Their willingness to share community-collected natural history data reflects years of patient-centred work, and this integration is what lets that work translate into research infrastructure that regulators and drug developers can actually build on.

It's a pattern C-Path plays a pivotal role in by establishing public-private partnerships and international programs across scientists and representatives from government, regulatory agencies, academia, patient organisations, disease foundations and pharmaceutical and biotech companies. Bringing together patient communities, high impact data, and research collaboration on the Aridhia DRE is a model that's leading to novel diagnostics and treatment options and improving our understanding of rare diseases.

For rare disease communities, that translation matters enormously. Integration with RWD like this doesn't just add more records to a platform in isolation. It helps close the loop between people living with a condition and the researchers trying to understand it, giving natural history data a faster, more direct route into the kind of standardised, analysis-ready form that can inform clinical trial design and support regulatory review.

Looking Ahead

This partnership marks another step in RDCA-DAP's growth as one of the largest platforms of its kind for rare and orphan disease data, and we're honoured the Aridhia DRE gets to be part of the infrastructure making it possible. As more data sources plug into RDCA-DAP through direct, continuous integrations like this one, the platform's value to researchers, and ultimately to patients, only compounds.

We look forward to continuing to support C-Path as RDCA-DAP grows, and to seeing what this expanded, more current view of rare disease data makes possible.

RDCA-DAP is open and accepting applications for use; researchers can apply at portal.rdca.c-path.org.

Read C-Path's full press release here.